Disease · MONDO_0001475
Comparisons in its trials40
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 40
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC: Number of Participants With Neutropenic Complications in Cycle 1 | 8 of 196 | 8 of 210 | 406 | NCT02643420 | Trial comparisons |
| Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC: Number of Participants With Febrile Neutropenia (FN) in Cycle 1 | 4 of 196 | 2 of 210 | 406 | NCT02643420 | Trial comparisons |
| (Arm 1): SPI-2012 and TC vs (Arm 2): Pegfilgrastim and TC: Number of Participants With Febrile Neutropenia (FN) in Cycle 1 | 1 of 118 | 4 of 119 | 237 | NCT02953340 | Trial comparisons |
| (Arm 1): SPI-2012 and TC vs (Arm 2): Pegfilgrastim and TC: Number of Participants With Neutropenic Complications in Cycle 1 | 1 of 118 | 5 of 119 | 237 | NCT02953340 | Trial comparisons |
| Immediate Voriconazole vs Deferred Voriconazole Treatment: serious adverse events | 8 of 81 | 8 of 66 | 147 | NCT00150345 | Trial comparisons |
| Immediate Voriconazole vs Deferred Voriconazole Treatment: Number of Participants Assessed as Needing Further Antineoplastic Therapy as Planned | 42 of 68 | 32 of 54 | 122 | NCT00150345 | Trial comparisons |
| Immediate Voriconazole vs Deferred Voriconazole Treatment: Number of Participants With Defervescence Day 5 (4 Days After Initiation of Study Treatment) | 32 of 68 | 28 of 54 | 122 | NCT00150345 | Trial comparisons |
| Granulocyte Arm vs Control Arm: Long-term Survival | 20 of 56 | 30 of 58 | 114 | NCT00627393 | Trial comparisons |
| Granulocyte Arm vs Control Arm: serious adverse events | 26 of 56 | 25 of 58 | 114 | NCT00627393 | Trial comparisons |
| Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: Number of Participants With Infection-related Mortality in the MITT Analysis Set at LFU | 0 of 47 | 0 of 50 | 97 | NCT03485950 | Trial comparisons |
| Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: Number of Participants With Favorable Clinical Response in the MITT Analysis Set at TOC | 34 of 47 | 28 of 50 | 97 | NCT03485950 | Trial comparisons |
| Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: 30 Day All-cause Mortality in the MITT Analysis Set | 2 of 47 | 2 of 50 | 97 | NCT03485950 | Trial comparisons |
| Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV) | 41 of 47 | 36 of 50 | 97 | NCT03485950 | Trial comparisons |
| Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: Number of Participants With Infection-related Mortality in the MITT Analysis Set at TOC | 0 of 47 | 0 of 50 | 97 | NCT03485950 | Trial comparisons |
| Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: Number of Participants With Favorable Clinical Response in the MITT Analysis Set at Late Follow-Up (LFU) | 33 of 47 | 26 of 50 | 97 | NCT03485950 | Trial comparisons |
| Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: deaths from any cause | 3 of 47 | 2 of 50 | 97 | NCT03485950 | Trial comparisons |
| Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: serious adverse events | 33 of 47 | 33 of 50 | 97 | NCT03485950 | Trial comparisons |
| Immediate Voriconazole vs Deferred Voriconazole Treatment: Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis | 6 of 43 | 9 of 35 | 78 | NCT00150345 | Trial comparisons |
| Methotrexate vs Cyclophosphamide: serious adverse events | 56 of 59 | 8 of 16 | 75 | NCT00003910 | Trial comparisons |
| Immediate Voriconazole vs Deferred Voriconazole Treatment: Number of Participants That Died on or Before Day 28 (Mortality) | 4 of 43 | 1 of 29 | 72 | NCT00150345 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001475/comparisons